Aelis Farma SA (EPA: AELIS)

Market Cap	155.39M
Revenue	12.36M
Net Income	-5.08M
Shares Out	13.63M
EPS	-0.39
PE Ratio	n/a
Forward PE	5.62
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2
Open	11.50
Previous Close	11.50
Day's Range	11.40 - 11.50
52-Week Range	11.40 - 13.85
Beta	0.11
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 16, 2024

About Aelis Farma

Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 26
• Stock Exchange: Euronext Paris
• Ticker Symbol: AELIS